Business Wire

MORINAGA-MILK-INDUSTRY

8.8.2024 20:01:28 CEST | Business Wire | Press release

Share
Morinaga Milk Obtains the Registration of "New Food Ingredient" in China for use of its Probiotic Bifidobacterium infantis M-63 in Infant Foods

Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, today announced its proprietary probiotic Bifidobacterium infantis M-63 was approved by the National Health Commission (NHC) of the People’s Republic of China as a new food ingredient for use in infant and children foods (under the age of three) on 25 July, 2024. This approval marks a significant milestone for the company, making it the only Japanese firm to have three bifidobacteria strains registered for use in China’s infant and toddler food market1.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240808893280/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Bifidobacterium infantis M-63 is a unique probiotic strain of human-residential bifidobacteria (HRB) – bifidobacteria that naturally reside in the human gut – and is renowned for its ability to utilize human milk oligosaccharides (HMO) found in breast milk, significantly improving the intestinal environment of healthy full-term infants. (Graphic: Business Wire)

*1 Source: Public announcement published on the website of the China National Center for Food Safety Risk Assessment (August 5, 2024)

The newly registered Bifidobacterium infantis M-63 joins Morinaga Milk’s other approved strains, Bifidobacterium breve M-16V and Bifidobacterium longum BB536. All three strains are now permitted for use in foods for children under three years old in China, meeting the country's stringent nutritional and safety standards.

Expanding Global Presence

This approval aligns with Morinaga Milk’s 10-year vision to become a globally recognized company with a significant international presence. As part of this vision, the company aims to achieve a Global Business sales ratio of 15% or more by the fiscal year ending in March 2029. The approval of Bifidobacterium infantis M-63 represents a strategic step towards this goal, allowing Morinaga Milk to strengthen its bacteria business in the Chinese market, which accounts for more than 40% of the global formula milk market and is the second-largest supplement market worldwide2.

*2 Source: Survey by Euromonitor International (May 2024), based on retail sales prices

Health Benefits of Bifidobacterium infantis M-63

Bifidobacterium infantis M-63 is a unique probiotic strain of human-residential bifidobacteria (HRB) – bifidobacteria that naturally reside in the human gut – and is renowned for its ability to utilize human milk oligosaccharides (HMO) found in breast milk, significantly improving the intestinal environment of healthy full-term infants. With China's recent approval of HMO use in formula milk in October 20233, the combination of Bifidobacterium infantis M-63 and HMO is expected to support the growth of beneficial intestinal bacteria, enhancing the development and health of infants and toddlers4.

*3 Source: National Health Commission of the People’s Republic of China, No. 8, 2023 (Sept. 22, 2023)
*4 Source: Mintel, “HMOs approval in China infant formula is a game changer” (Jan. 2024)

Probiotics strain of bifidobacteria registered as New Food Ingredients in China

Strain

Registration date

Bifidobacterium breve M-16V

Registered name: 短双歧杆菌 M-16V

2016

Bifidobacterium longum subsp. longum BB536

Registered name: 长双歧杆菌长亚种 BB536

2022

Bifidobacterium longum subsp. infantis M-63

Registered name: 长双歧杆菌婴儿亚种M-63

2024

* All three strains are approved for use in foods for infants and toddlers under the age of three.

Commitment to Quality and Research

Morinaga Milk has been at the forefront of bifidobacteria research since discovering Bifidobacterium longum BB536 in 1969. The company leads globally in the number of clinical research papers on bifidobacteria, underlining its commitment to advancing scientific understanding and improving public health.

Future Prospects

The registration of Bifidobacterium infantis M-63 paves the way for its use in a wide range of products. Morinaga Milk plans to leverage this approval to expand collaborations with major formula milk manufacturers and promote supplements and other related products in China and globally. By providing accurate information on the benefits of Bifidobacterium infantis M-63 to consumers and partners, Morinaga Milk aims to enhance the health and nutrition of people worldwide.

About Morinaga Milk Industry

Morinaga Milk Industry Co., Ltd. is one of the leading dairy product companies in Japan, with over a century of history in harnessing the nutritional properties of dairy products and functional ingredients. Morinaga Milk is also a key global probiotics manufacturer that excels in innovative technology and offers a premium line of probiotics and functional ingredients worldwide. Since the 1960s, Morinaga Milk has been engaged in research on the safety, functional health benefits, and mechanisms of action of probiotic bifidobacteria to better understand their role in maintaining human health. For more information about Morinaga Human-Residential Bifidobacteria (HRB) probiotics, please visit us at https://morinagamilk-ingredients.com/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240808893280/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Dream Accelerates Growth of Asset Management Platform With Acquisition of Chancerygate, a Leading U.K.-Based Industrial Asset Manager and Developer31.7.2026 00:09:00 CEST | Press release

Combined platform is one of Europe’s leaders in urban industrial with over 80 professionals and 27 million square feet of GLA managed or under development across nine countries. Dream Unlimited Corp. (“Dream”) (TSX: DRM) today announced that Dream and Dream Industrial Real Estate Investment Trust (“Dream Industrial REIT”) (TSX: DIR.UN), have entered into definitive agreements for Dream to acquire Chancerygate Limited (“Chancerygate” or “CG”), a U.K.-based industrial developer and asset manager with a 30-year track record in the multi-let industrial (“MLI”) sector. Chancerygate currently manages a diversified portfolio of income producing and development assets totaling £1.2 billion ($2.2 billion). As part of the transaction, Dream will assume Chancerygate's investment management and development platform. Dream Industrial REIT will acquire Chancerygate's wholly owned real estate assets and co-investment interests across its managed ventures for consideration of approximately £78 million

Dream Industrial REIT Announces Entry Into U.K. Multi-Let Industrial Market and Growth of Strategic Private Ventures in Europe31.7.2026 00:06:00 CEST | Press release

This press release contains forward-looking information that is based upon assumptions and is subject to risks and uncertainties as indicated in the cautionary note contained within this press release. All dollar amounts are in Canadian dollars unless otherwise indicated. Dream Industrial Real Estate Investment Trust (TSX: DIR.UN) (the “Trust” or the “REIT” or “DIR”) today announced that the Trust and Dream Unlimited Corp. (TSX: DRM) (“Dream”), have entered into definitive agreements for Dream to acquire Chancerygate Limited (“Chancerygate” or “CG”), a U.K.-based industrial developer and asset manager with a 30-year track record in the multi-let industrial (“MLI”) sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730297448/en/ Audio Park, Sussex, UK - 104,000 sq ft As part of the transaction, Dream will assume Chancerygate's investment management and development platform. Dream Industrial REIT will acquire Chanceryga

Rimini Street Announces Fiscal Second Quarter 2026 Financial and Operating Results30.7.2026 22:03:00 CEST | Press release

Second Quarter Financial Highlights Include: Revenue of $111.1 million, up 6.7% year over year Adjusted Revenue of $108.0 million, up 10.0% year over year Remaining Performance Obligations (RPO) of $636.9 million, up 8.0% year over year Adjusted Annualized Recurring Revenue of $401.1 million, up 8.1% year over year Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the fiscal second quarter ended June 30, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730702735/en/ Rimini Street Announces Fiscal Second Quarter 2026 Financial and Operating Results “Second-quarter results and four consecutive quarters of improved growth metrics demonstrate strong demand for our core Rimini Support™ offering, increasing adop

Rimini Street Launches Rimini Govern™ for AI to Deliver Comprehensive AI Agent Governance, Security & Interoperability as a Service30.7.2026 22:01:00 CEST | Press release

The new service enables organizations to quickly and easily implement and operationalize a global, enterprise-wide governance, control, security and performance measurement solution for AI agent activity and workflows Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced the immediate availability of Rimini Govern™ for AI, the newest offering in the company’s Rimini Govern portfolio of Governance, Risk and Compliance (GRC) solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730389723/en/ Rimini Street Launches Rimini Govern™ for AI to Deliver Comprehensive AI Agent Governance, Security & Interoperability as a Service The new managed service is delivered 24/7/365 through Rimini Street’s Global Command Centers by expert AI engineers to help organizations: Accelerate AI agent deployment Reduc

One Biosciences Announces Data Validating New Method for Single-Cell Transcriptomic Tumor Profiling from Clinical Pathology Samples30.7.2026 21:03:00 CEST | Press release

Sample-to-report workflow generating single-cell RNA expression profiles using routine FFPE pathology slides from four institutions validated across 88 specimens and six cancer types One Biosciences, a techbio company pioneering clinical-grade single-cell tumor profiling, today announced data establishing that single-cell RNA expression profiles can be generated from the standard, formalin-fixed paraffin-embedded (FFPE) pathology specimens obtained in routine cancer care using the company’s proprietary platform, OneMap™. The study, conducted with collaborators at Centre Léon Bérard, Hôpital Bichat–Claude Bernard, Institut Curie, and Memorial Sloan Kettering Cancer Center, was released as a preprint on BiorXiv. “Every tumor is a unique ecosystem of many different types of cells, some cancerous, some not. Single cell profiling enables us to understand what those cells are, what they’re doing and potentially how that may impact treatment outcomes,” said Helena Yu, MD, thoracic medical onc

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye